12 Health Care Stocks Moving In Tuesday's After-Market Session

Benzinga Insights 3 hours ago

Movers

Gainers Nordicus Partners (NASDAQ:NORD) stock increased by 10.8% to $4.5 during Tuesday's after-market session. The market value of their outstanding shares is at $71.5 million. Gelteq (NASDAQ:GELS) shares rose

Gainers

  • Nordicus Partners (NASDAQ:NORD) stock increased by 10.8% to $4.5 during Tuesday's after-market session. The market value of their outstanding shares is at $71.5 million.
  • Gelteq (NASDAQ:GELS) shares rose 8.95% to $0.49. The market value of their outstanding shares is at $5.2 million.
  • Matinas BioPharma Hldgs (AMEX:MTNB) stock moved upwards by 7.0% to $1.11. The market value of their outstanding shares is at $18.9 million.
  • 20/20 Biolabs (NASDAQ:AIDX) stock increased by 6.47% to $0.25. The company's market cap stands at $3.0 million.
  • Karyopharm Therapeutics (NASDAQ:KPTI) stock moved upwards by 6.11% to $0.09. The market value of their outstanding shares is at $2.5 million.
  • Scinai Immunotherapeutics (NASDAQ:SCNI) shares increased by 5.22% to $0.48.

Losers

  • Nurix Therapeutics (NASDAQ:NRIX) shares fell 22.6% to $20.0 during Tuesday's after-market session. The company's market cap stands at $2.8 billion.
  • Nuwellis (NASDAQ:NUWE) shares decreased by 11.17% to $5.25. The market value of their outstanding shares is at $2.0 million.
  • Onconetix (NASDAQ:ONCO) shares decreased by 9.48% to $0.52. The market value of their outstanding shares is at $3.1 million.
  • Ultragenyx Pharmaceutical (NASDAQ:RARE) stock decreased by 9.21% to $15.1. The company's market cap stands at $1.6 billion. As per the news, the Q3 earnings report came out today.
  • Baird Medical Investment (NASDAQ:BDMD) shares declined by 5.9% to $0.11. The market value of their outstanding shares is at $4.4 million.
  • BeyondSpring (NASDAQ:BYSI) shares declined by 5.16% to $0.59. The market value of their outstanding shares is at $33.1 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Read the original